The use of GnRH agonists in the treatment of endometriomas with or without drainage.

Sertaç Batıoğlu, S Batioglu, H Celikkanat, H. Çelikkanat, M Ugur, Mete Gürol Uğur, L Mollamahmutoglu, Leyla Mollamahmutoğlu, Hüseyin Yeşilyurt, H Yesilyurt, Meral Kundakçi, M Kundakci
JPMA. The Journal of the Pakistan Medical Association · 1996 · vol. 46(2) , pp. 30–2 · PMID:8683844 · W25576511
article OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

Combining cyst drainage with postoperative GnRH-agonist suppression achieved 100% reduction in ovarian endometrioma size and 37% complete resolution, superior to GnRH-agonist therapy alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To assess the efficacy of GnRH-agonist therapy in the treatment of endometriomas with or without surgical intervention, 26 women with laparoscopically proven endometriomas larger than 3 cm were recruited to the study. Fourteen women with 19 endometriomas (5 bilateral), had drainage of endometrioma at initial laparoscopy. After the procedure, ovarian suppression was done with GnRH-a therapy for 6 months. The second group which consisted of 12 women, had 17 endometriomas. No surgical procedure was performed. They received only GnRH-a therapy for 6 months. On repeat laparoscopy, in the first group, the rates of decrease in ovarian AFS scores of endometriomas and complete resolution were found as 100% and 37% respectively. In the second group the response was only 18% (p < 0.0001). It was concluded that drainage of the cyst (surgical therapy) combined with postoperative GnRH-a suppression is a better treatment modality than the use of GnRH-a (medical therapy) alone for endometriomas.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Endometriosis Laparoscopy Ovarian Diseases Triptorelin Pamoate Adult Combined Modality Therapy Drainage Endometriosis Female Humans Ovarian Diseases Triptorelin Pamoate Triptorelin Pamoate

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (19)

Cited by (12)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:08.331550+00:00
License: CC0 · commercial use OK